Cocrystal Pharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cocrystal Pharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2011 | $12.71M | Apr 1, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $2.01M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $6.56M | Mar 17, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $7.22M | Apr 1, 2013 |
| FY2011 | Dec 31, 2011 | $3.97M | Apr 16, 2012 |
| FY2011 | Dec 31, 2010 | $6.83M | Apr 16, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.83M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($17.50M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($17.98M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($38.84M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($14.19M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($9.65M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($48.17M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($49.05M) | Mar 27, 2020 |
| FY2017 | Dec 31, 2017 | $4.90M | Mar 21, 2018 |
| FY2017 | Sep 30, 2017 | ($1.96M) | Mar 21, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.02M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($17.88M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($18.56M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($38.83M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($14.22M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($9.59M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($48.41M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($62.92M) | Mar 27, 2020 |
| FY2017 | Dec 31, 2017 | ($1.83M) | Mar 21, 2018 |
| FY2017 | Sep 30, 2017 | ($2.11M) | Mar 21, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.06M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $12.54M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $15.17M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.39M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $8.79M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $6.03M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $4.00M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $4.67M | Mar 27, 2020 |
| FY2017 | Dec 31, 2017 | $1.10M | Mar 21, 2018 |
| FY2017 | Sep 30, 2017 | $1.39M | Mar 21, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.19M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($16.49M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($14.67M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($21.44M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($12.72M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($9.83M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($1.56M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($8.29M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($6.90M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($14.66M) | Mar 21, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $118.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $74.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $52.0K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $240.0K | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $145.0K | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $28.0K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $40.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $51.0K | Mar 21, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.71M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.46M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $31.26M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $40.84M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $79.39M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $54.24M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $28.53M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $68.56M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $121.43M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $124.88M | Mar 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.38M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.93M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.88M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.27M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.84M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $1.74M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $2.82M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $1.67M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $16.03M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $22.56M | Mar 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.33M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.52M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $26.38M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $39.60M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $77.55M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $52.51M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $25.71M | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | $66.89M | Mar 17, 2021 |
| FY2019 | Dec 31, 2017 | $105.40M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $102.32M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2021 | $19.09M | Mar 28, 2024 |
| FY2021 | Dec 31, 2020 | $19.09M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $19.09M | Mar 17, 2021 |
| FY2020 | Dec 31, 2018 | $65.20M | Mar 17, 2021 |
| FY2019 | Dec 31, 2017 | $65.20M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $65.20M | Apr 1, 2019 |
| FY2016 | Dec 31, 2015 | $65.20M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $65.20M | Mar 15, 2016 |
| FY2012 | Dec 31, 2012 | $1.03M | Apr 1, 2013 |
| FY2012 | Dec 31, 2011 | $1.03M | Apr 1, 2013 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($342.25M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($333.42M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($315.91M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($297.93M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($259.09M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($244.91M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($235.26M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($187.09M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($138.04M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($137.43M) | Mar 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.03M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.86M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $26.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $37.14M | Mar 28, 2024 |
| FY2021 | Dec 31, 2021 | $58.71M | Mar 23, 2022 |
| FY2021 | Dec 31, 2020 | $33.01M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $7.42M | Mar 17, 2021 |
| FY2017 | Dec 31, 2017 | $748.0K | Mar 21, 2018 |
| FY2017 | Dec 31, 2016 | $3.61M | Mar 21, 2018 |
| FY2016 | Dec 31, 2015 | $9.28M | Mar 31, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $49.94M | Mar 15, 2016 |
| FY2015 | Dec 31, 2014 | $65.26M | Mar 15, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
| FY2017 | Dec 31, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Mar 31, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Dec 31, 2016 | (3) | Mar 21, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 28, 2024 |
| FY2017 | Dec 31, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Mar 31, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Dec 31, 2016 | (3) | Mar 21, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Mar 21, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.78M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 10.17M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 10.17M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 8.14M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 8.14M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 70.44M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | 35.15M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | 29.94M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 24.28M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 23.80M | Mar 21, 2018 |